These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 6416260)

  • 1. [Beta-propiolactone as a sterilizing agent in the manufacture of intravenous immunoglobulin preparations].
    Stephan W; Dichtelmüller H
    Arzneimittelforschung; 1983; 33(9):1230-1. PubMed ID: 6416260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Human i.v. immune globulin by chemical modification with beta-propiolactone/radiochemical study (author's transl)].
    Stephan W; Fasold H
    Arzneimittelforschung; 1980; 30(12):2090-3. PubMed ID: 7194066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the mutagenicity and immunogenicity of a beta-propiolactone-treated therapeutic IgG-preparation.
    Pincus JH; Mortelmans K; Tanaka W; Stephan W; Lissner R
    Arzneimittelforschung; 1981; 31(11):1924-8. PubMed ID: 6172136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Placental transfer of class G immunoglobulins treated with beta-propiolactone (beta-PL) for intravenous application--a case report.
    Höckel M; Kaufmann R
    J Perinat Med; 1986; 14(3):205-8. PubMed ID: 3783391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivation of hepatitis viruses and HIV in plasma and plasma derivatives by treatment with beta-propiolactone/UV irradiation.
    Stephan W
    Curr Stud Hematol Blood Transfus; 1989; (56):122-7. PubMed ID: 2642784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Inactivation of hepatitis non-A, non-B virus in intravenous immunoglobulins by beta-propiolactone].
    Dichtelmüller H; Stephan W; Prince AM; Brotman B
    Beitr Infusionsther; 1988; 21():202-4. PubMed ID: 2462976
    [No Abstract]   [Full Text] [Related]  

  • 7. [Beta-propiolactone for cold sterilization of heart valve transplants].
    Wutzler P; Sprössig M; Wenzel KP; Mücke H
    Z Exp Chir; 1975; 8(4):236-40. PubMed ID: 1053182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chemical modification with beta-propiolactone as a general concept for the production of intravenously tolerable immunoglobulin preparations].
    Stephan W
    Beitr Infusionther Klin Ernahr; 1983; 11():20-5. PubMed ID: 6686024
    [No Abstract]   [Full Text] [Related]  

  • 9. Virus safety of beta-propiolactone treated plasma preparations. Clinical experiences.
    Heinrich D; Sugg U; Brackmann HH; Stephan W; Lissner R
    Dev Biol Stand; 1987; 67():311-7. PubMed ID: 3649316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences among available immunoglobulin preparations for intravenous use.
    Skvaril F; Gardi A
    Pediatr Infect Dis J; 1988 May; 7(5 Suppl):S43-8. PubMed ID: 2456510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinical study of the tolerance and safety of a beta-propiolactone-treated immunoglobulin.
    Mondorf AW; Stephan W; Uthemann H; Schuppan D; Lissner R
    Arzneimittelforschung; 1981; 31(11):1928-30. PubMed ID: 6797445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivation of the Hutchinson strain of hepatitis non-A, non-B virus in intravenous immunoglobulin by beta-propiolactone.
    Stephan W; Dichtelmüller H; Prince AM; Brotman B; Huima T
    J Med Virol; 1988 Nov; 26(3):227-32. PubMed ID: 3144576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of in vitro behaviour and in vivo efficacy of two 7S-immunoglobulin preparations for intravenous use.
    Stephan W; Dichtelmüller H
    Arzneimittelforschung; 1983; 33(11):1538-40. PubMed ID: 6686449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Principles of selective inactivation of the viral genome. III. Kinetics of the inactivation of bacteriophage MS2 infectivity by beta-propiolactone].
    Budovskiĭ EI; Zalesskaia MA
    Mol Biol (Mosk); 1985; 19(4):1139-47. PubMed ID: 4047036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cultivation of mycoplasma in fluid media sterilized with beta-propiolactone].
    Kiuntsel' V; Starost E; Meissner Kh
    Vestn Akad Med Nauk SSSR; 1976; (5):60-2. PubMed ID: 969882
    [No Abstract]   [Full Text] [Related]  

  • 16. [Beta-propiolactone as a sterilizing agent in the preparation of homo- and heterologous bone transplants].
    Savel'ev VI
    Ortop Travmatol Protez; 1966 Apr; 27(4):53-6. PubMed ID: 4864694
    [No Abstract]   [Full Text] [Related]  

  • 17. Influence of hydroxylamine and beta-propiolactone on the kinetics of plaque growth of SP3 and SP8 phages of Bacillus subtilis.
    Kaláb D
    Acta Virol; 1968 Jul; 12(4):367-70. PubMed ID: 4386022
    [No Abstract]   [Full Text] [Related]  

  • 18. Undegraded human immunoglobulin for intravenous use.
    Stephan W
    Vox Sang; 1975; 28(6):422-37. PubMed ID: 807036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of beta-propiolactone in blood on routine haematological, biochemical, and serological investigations.
    Freeman R; Codd AA; Selkon JB
    Lancet; 1982 May; 1(8280):1048-9. PubMed ID: 6122856
    [No Abstract]   [Full Text] [Related]  

  • 20. Inactivation of hepatitis A virus added to pooled human plasma by beta-propiolactone treatment and ultraviolet irradiation.
    Frösner GG; Stephan W; Dichtelmüller H
    Eur J Clin Microbiol; 1983 Aug; 2(4):355-7. PubMed ID: 6313360
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.